Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco
HEIDELBERG, Germany, Jan. 7, 2014 /PRNewswire/ — Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present the results of the completed phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Francisco. The presentation will take place on Tuesday, Jan. 14, at 4 p.m. PST at the Parc 55 Wyndham San Francisco – Union Square.
“The results of this controlled phase II trial represent the most important milestone since Apogenix was founded,” said Thomas Hoeger. “We are actively discussing the further development of APG101 toward approval with the regulatory authorities.”
Apogenix develops protein therapeutics that could transform the treatment of life-threatening diseases by targeting critical pathways involved in the growth, migration, and apoptosis of diseased cells. The company’s lead drug candidate APG101 is currently being evaluated in patients with glioblastoma – a disease with a tremendous need for new and effective therapies.
Apogenix’ lead drug candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc portion of an IgG antibody. The interaction between the CD95 ligand and the CD95 receptor activates an intracellular signaling pathway that stimulates the invasive growth and migration of tumor cells, such as glioblastoma cells. APG101 binds to the CD95 ligand and thus inhibits activation of the CD95 signaling pathway, resulting in reduced tumor cell growth and migration.
Media Contacts USA: Europe: Martina Schwarzkopf, Ph.D. Raimund Gabriel Russo Partners, LLC MC Services AG Phone: +1 (212) 845 4292 Phone: +49 (89) 210 228 30 email@example.com firstname.lastname@example.org